Next Article in Journal
Transdermal Delivery of Drugs with Microneedles—Potential and Challenges
Next Article in Special Issue
Neurosurgical Techniques for Disruption of the Blood–Brain Barrier for Glioblastoma Treatment
Previous Article in Journal
Effect of the Compaction and the Size of DNA on the Nuclear Transfer Efficiency after Microinjection in Synchronized Cells
Previous Article in Special Issue
Liposomal Conjugates for Drug Delivery to the Central Nervous System
Article Menu

Export Article

Open AccessReview
Pharmaceutics 2015, 7(2), 74-89; doi:10.3390/pharmaceutics7020074

Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena 41124, Italy
Nanomedicine Group, Te.Far.T.I. Center, Department of Life Sciences, University of Modena and Reggio Emilia, Modena 41124, Italy
Author to whom correspondence should be addressed.
Academic Editor: Gert Fricker
Received: 30 March 2015 / Revised: 15 May 2015 / Accepted: 10 June 2015 / Published: 19 June 2015
(This article belongs to the Special Issue Drug Delivery to Brain)
View Full-Text   |   Download PDF [1629 KB, uploaded 19 June 2015]   |  


The success of nanomedicine as a new strategy for drug delivery and targeting prompted the interest in developing approaches toward basic and clinical neuroscience. Despite enormous advances on brain research, central nervous system (CNS) disorders remain the world’s leading cause of disability, in part due to the inability of the majority of drugs to reach the brain parenchyma. Many attempts to use nanomedicines as CNS drug delivery systems (DDS) were made; among the various non-invasive approaches, nanoparticulate carriers and, particularly, polymeric nanoparticles (NPs) seem to be the most interesting strategies. In particular, the ability of poly-lactide-co-glycolide NPs (PLGA-NPs) specifically engineered with a glycopeptide (g7), conferring to NPs’ ability to cross the blood brain barrier (BBB) in rodents at a concentration of up to 10% of the injected dose, was demonstrated in previous studies using different routes of administrations. Most of the evidence on NP uptake mechanisms reported in the literature about intracellular pathways and processes of cell entry is based on in vitro studies. Therefore, beside the particular attention devoted to increasing the knowledge of the rate of in vivo BBB crossing of nanocarriers, the subsequent exocytosis in the brain compartments, their fate and trafficking in the brain surely represent major topics in this field. View Full-Text
Keywords: nanomedicine; blood brain barrier; neuron; endocytosis; cellular uptake nanomedicine; blood brain barrier; neuron; endocytosis; cellular uptake

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Vilella, A.; Ruozi, B.; Belletti, D.; Pederzoli, F.; Galliani, M.; Semeghini, V.; Forni, F.; Zoli, M.; Vandelli, M.A.; Tosi, G. Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles. Pharmaceutics 2015, 7, 74-89.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top